Y Intercept Hong Kong Ltd Buys New Position in Mesa Laboratories, Inc. $MLAB

Y Intercept Hong Kong Ltd purchased a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,315 shares of the medical instruments supplier’s stock, valued at approximately $558,000. Y Intercept Hong Kong Ltd owned approximately 0.11% of Mesa Laboratories as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its position in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesa Laboratories during the fourth quarter worth $27,000. Kestra Advisory Services LLC purchased a new position in shares of Mesa Laboratories in the fourth quarter valued at $55,000. BNP Paribas Financial Markets boosted its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 684 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Insider Buying and Selling at Mesa Laboratories

In related news, SVP Brian David Archbold sold 2,516 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the sale, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO John Sakys sold 2,827 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares in the company, valued at approximately $1,770,757.50. This represents a 12.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,277 shares of company stock worth $770,122 in the last ninety days. 4.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Price Performance

Shares of NASDAQ MLAB opened at $94.95 on Tuesday. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. Mesa Laboratories, Inc. has a fifty-two week low of $55.45 and a fifty-two week high of $113.99. The business has a 50 day moving average price of $101.69 and a two-hundred day moving average price of $93.05. The firm has a market cap of $524.12 million, a PE ratio of 79.12 and a beta of 0.93.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. The business had revenue of $63.72 million during the quarter, compared to analyst estimates of $65.21 million. During the same period in the previous year, the company earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio is 53.33%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.